News

Study of Green Tea Extract May Yield Key to Hearing Protection for Cancer Patients

Published Date:

SPRINGFIELD, ILLINOIS: If you could take a drug that would help cure your cancer, but it would make you go deaf, would you still take the drug?

Cisplatin is a widely used anticancer drug that unfortunately carries some major side effects, including hearing loss and damage to the nerves and kidneys. Its high toxicity often requires dose reductions or the use of less effective alternate drugs.

Cisplatin-induced hearing loss can range from 50-75 percent in adults. When the drug is used to treat neuroblastomas in pediatric cancer patients, extreme care must be taken because hearing loss can hamper speech, cognition and social development of the child.

Vickram Ramkumar, PhD, professor of pharmacology at SIU School of Medicine, has received a new $2.3 million grant from the National Institutes of Health (NIH) to explore the properties of a green tea extract, epigallocatechin gallate (EGCG), which offers protection against cisplatin-induced hearing loss. It builds upon his lab’s ototoxicity research with Debashree Mukherjea, PhD, assistant research professor, and Leonard Rybak, MD, professor emeritus, both in the Division of Otolaryngology, Department of Surgery.

“Chemotherapy can be daunting, so anything you can do to end a side effect and ease the patient’s recovery is a win,” said Dr. Ramkumar. “We are encouraged that our studies could lead to the design of a safer treatment for cancer care.”

The research team had earlier identified a protein called signal transducer and activator of transcription 1 (STAT1) that is involved in the activation of inflammation and cell death pathway in the ear induced by cisplatin. The new studies will test how STAT1 is affected by different doses of the green tea extract EGCG, and examine if it has different benefits by gender and by timing of the doses. The group will also examine whether EGCG interferes with the anticancer benefits of cisplatin, as these drugs will be administered together to treat cancer (cisplatin) or reduce hearing loss (EGCG).

More from SIU News

Jones on Mars

SIU alumnus shares lessons learned during a year on Mars

On Sept. 26, SIU alumnus Dr. Nathan Jones discussed his year-long NASA simulation mission in a detailed and entertaining presentation in the South Auditorium. The Springfield emergency medicine
White Coat pledge

Physician Assistant, DMSc programs celebrate 2024 graduates & new students

The SIU School of Medicine Physician Assistant (PA) community kicked off August with three key celebratory events that showcased the dedication, achievements and future aspirations of its students and faculty.
Jensik inventor award

Jensik honored as SIU Inventor of the Year

Phil Jensik, PhD, associate professor in SIU School of Medicine’s Department of Physiology, has been named SIU’s Inventor of the Year for 2024. His research explores mutations in genes that result in neurodevelopmental disorders such as intellectual disabilities, speech disorders and autism, affecting about 1 in 10 U.S. children.